Drugs Aid Metastatic RCC Outcomes

March 01 2007

TWO RELATIVELY new oral agents can improve outcomes for patients with metastatic renal cell carcinoma (RCC), according to recent reports. The drugs, sunitinib and sorafenib, inhibit enzymes that promote angiogenesis and thus may act by disrupting tumor vasculature.

<< Return to Drugs Aid Metastatic RCC Outcomes

Your Email Address:

Recipient(s) Email Address:

(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)

Include a message (optional):

The e-mail address(es) that you supply to use this service will only be used to send the requested article.